PINK:PHRRF
Newscope Capital Corporation Stock News
$0.150
-0.0005 (-0.333%)
At Close: Jun 25, 2024
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
08:00am, Wednesday, 15'th May 2024
Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, developme
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
07:59am, Friday, 10'th May 2024
TORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of an
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
08:50am, Wednesday, 01'st May 2024
Toronto, Ontario--(Newsfile Corp. - May 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, developmen
PharmaTher's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
08:00am, Wednesday, 01'st May 2024
TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Thera
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
04:00pm, Thursday, 18'th Apr 2024
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
08:00am, Tuesday, 16'th Apr 2024
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its P
PharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
09:30am, Wednesday, 21'st Feb 2024
TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Ther
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
08:00am, Monday, 12'th Feb 2024
TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Pr
PharmaTher Provides Update for Expected FDA Approval of Ketamine
07:30am, Wednesday, 10'th Jan 2024
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, is pleased to provide an upd
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
07:30am, Wednesday, 27'th Sep 2023
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher's commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE)
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
07:30am, Wednesday, 06'th Sep 2023
TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleas
TORONTO, July 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is please
PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.
07:30am, Tuesday, 18'th Jul 2023
Toronto, Ontario--(Newsfile Corp. - July 18, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), announced today that it has reached an agreement yesterday with PharmaT
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson's Disease
09:03am, Wednesday, 06'th Oct 2021
“KET-LID” trial to evaluate ketamine's safety and efficacy in the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease “KET-LID” trial to evaluate ketamine's safety an
PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors
05:41pm, Tuesday, 28'th Sep 2021
TORONTO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM)(OTCQB: PHRRF), a clinical-stage psychedelics biotech company, is pleased to ann
